Capturing Tumor Complexity and Diversity with Organoid and Patient-Derived Xenograft Models

One of the longstanding challenges in oncology research is representing the full biological diversity of human cancers. Widely used traditional cancer cell lines often fail to reflect the histological and genetic characteristics of actual patient tumors, particularly over time. In contrast, patient-derived organoids and tumor graft models preserve the architecture, molecular integrity, and phenotypic behavior of their original tissue. These are two examples of new approach methodologies (NAMs) that are reducing reliance on animal models for various aspects of drug discovery, development, and testing.

Tumor organoids are three-dimensional structures cultured from patient-derived tumor samples that support both precision medicine approaches and large-scale drug discovery efforts. They retain crucial features such as cell-cell interaction, differentiation gradients, and key signaling pathways while providing a scalable and reproducible system for modeling disease. Organoids can be derived from small, fine-needle biopsies and reflect a wide range of cancer types, including those from rare or difficult-to-access indications, such as brain tumors.

Patient-derived xenograft systems serve as an essential extension of this approach as they mimic the host environment in a biologically relevant setting that maintains the tumor’s genetic and histopathological fidelity. As such, these systems allow researchers to study tumor progression, treatment response, and resistance over time.

Driving drug discovery with greater predictive power

Translational oncology research relies heavily on clinically relevant preclinical models that can predict how therapies will perform in human patients. Patient-derived organoids are well suited to high-throughput screening, compound profiling, and biomarker discovery. When established from diverse patient backgrounds, they enable researchers to explore interpatient variability and uncover population-level trends in therapeutic response.

These systems support genomic, transcriptomic, and proteomic profiling to correlate molecular features with drug sensitivity. Their compatibility with technologies such as CRISPR screening, imaging-based assays, and multiplexed analysis makes them a versatile platform to understand mechanism of action, identify therapeutic vulnerabilities. and develop personalized treatment strategies.

In parallel, tumor-derived graft models play a vital role in confirming findings generated in vitro. They enable researchers to validate efficacy, pharmacodynamics, and resistance mechanisms in a context that preserves the spatial organization and cellular diversity of the tumor.

Understanding resistance to therapy

Drug resistance remains one of the greatest barriers in oncology. Whether intrinsic or acquired, resistance mechanisms can significantly limit treatment efficacy. Patient-derived organoids and graft-based systems offer powerful ways to model and dissect resistance in a setting that closely mirrors the clinical experience. For example, exposing organoids to therapies over time can produce resistant lines that mirror the emergence of resistance observed in patients. These models help uncover the drivers of resistance and identify novel targets or combination therapies to overcome it.

Moreover, panels of resistant and sensitive models allow for comparative studies across different tumor types or patient subgroups. This approach enhances the development of rational drug combinations and adaptive treatment strategies that can be tailored to real-world clinical scenarios.

Practical considerations as organoid research proliferates

In the USA, NAMs that serve as an alternative to animal models are increasingly embraced by academia, industry, and regulatory agencies. In late 2022, the FDA Modernization Act 2.0 was signed into law, overriding the agency’s longstanding requirement for all therapies to undergo animal testing prior to human use. In April 2025, the agency announced more ambitious plans to phase out all animal testing in the development of monoclonal antibodies. While the focus of these initial efforts is typically toxicity testing with no impact on efficacy studies, it underscores the validity of patient-derived organoids and AI-based in silico methods for research and drug development. In its announcement, the FDA formally recognized the many advantages NAMs confer, including cost- and time-efficiency, safety, and the ethical imperative to reduce the use of animals in research. This support is boosting a field that is already rich with innovation and progress.

As organoid use becomes more widespread, researchers are refining best practices for culture, handling, and data interpretation. Establishment rates can vary by tumor type and sample quality, making optimization essential. Factors such as passage number, growth conditions, and consistency in culture methods significantly affect experimental outcomes. Cryopreservation protocols and recovery workflows are also critical to maintaining model fidelity. Well-maintained organoid banks can serve as a resource for longitudinal studies and population-scale screening, while preserving the biological characteristics of the source tumors.

Reshaping the field of translational oncology

Patient-derived organoid and xenograft models are reshaping the field of translational oncology. By delivering greater biological relevance and preserving patient-specific features, they offer a clearer, more predictive path from discovery to the clinic. As the demand for precision oncology continues to grow, these models will remain at the forefront of efforts to understand cancer complexity, personalize therapy, and ultimately improve patient outcomes.